Expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor α in resected acute colonic diverticulitis

Colorectal Disease

Volumn 16, Issue 3, 2014, Pages

  Tursi, A ^a   Elisei, W ^b   Giorgetti, G M ^c   Inchingolo, C D ^d   Nenna, R ^d   Picchio, M ^e   Giorgio, F ^f   Ierardi, E ^f   Brandimarte, G ^g  

^a ASL BAT   (Italy)

^b ASL Roma H   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

^d 'Lorenzo Bonomo' Hospital   (Italy)

^e 'Paolo Colombo' Hospital   (Italy)

^f UNIVERSITY OF FOGGIA   (Italy)

^g 'Cristo Re' Hospital   (Italy)

Author keywords

Basic fibroblastic growth factor; Colonic diverticulitis; Syndecan 1; Tumour necrosis factor

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; FIBROBLAST GROWTH FACTOR 2; INFLIXIMAB; MESSENGER RNA; STEROID; SYNDECAN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; COLON DIVERTICULOSIS; COLON RESECTION; CONTROLLED STUDY; CROHN DISEASE; FEMALE; GENE EXPRESSION ASSAY; HEMICOLECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; INTESTINE BIOPSY; INTESTINE STENOSIS; LYMPHOCYTIC INFILTRATION; MALE; MIDDLE AGED; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; T LYMPHOCYTE; VERY ELDERLY;

BASIC FIBROBLASTIC GROWTH FACTOR; COLONIC DIVERTICULITIS; SYNDECAN 1; TUMOUR NECROSIS FACTOR Α;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; COLON; CROHN DISEASE; DIVERTICULITIS, COLONIC; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNDECAN-1; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84893730344     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.12504     Document Type: Article

References (34)

1. Tursi A, Papagrigoriadis S. Review article: the current and evolving treatment of colonic diverticular disease. Aliment Pharmacol Ther 2009; 30: 532-46.
2. Tursi A. New physiopathological and therapeutic approaches to diverticular disease of the colon. Expert Opin Pharmacoter 2007; 8: 299-307.
3. Rosemar A, Ivarsson ML, Borjesson L et al. Increased concentration of tissue-degrading matrix metalloproteinases and their inhibitor in complicated diverticular disease. Scand J Gastroenterol 2007; 2: 215-20.
4. Kovacs EJ, DiPietro LA. Fibrogenic cytokines and connective tissue production. FASEB J 1994; 11: 854-61.
5. Baragi VM, Qiu L, Gunja-Smith Z, Woessner JF Jr, Lesch CA, Guglietta A. Role of metalloproteinases in the development and healing of acetic acid-induced gastric ulcer in rats. Scand J Gastroenterol 1997; 5: 419-26.
6. Bailey CJ, Hembry RM, Alexander A, Irving MH, Grant ME, Shuttleworth CA. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol 1994; 2: 113-6.
7. Baugh MD, Perry MJ, Hollander AP et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999; 4: 814-22.
8. Salmela MT, MacDonald TT, Black D et al. Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridisation. Gut 2002; 4: 540-7.
9. Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P, Kere J, Saarialho-Kere U. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol 1998; 4: 1005-14.
10. Vizoso FJ, González LO, Corte MD et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 2007; 6: 903-11.
11. von Lampe B, Barthel B, Coupland SE et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000; 1: 63-73.
12. Warnaar N, Hofker HS, Maathuis MH et al. Matrix metalloproteinases as profibrotic factors in terminal ileum in Crohn's disease. Inflamm Bowel Dis 2006; 9: 863-9.
13. Altadill A, Eiró N, González LO et al. Comparative analysis of the expression of metalloproteases and their inhibitors in resected Crohn's disease and complicated diverticular disease. Inflamm Bowel Dis 2012; 18: 120-30.
14. Plevy SE, Landers CJ, Prehn J et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997; 159: 6276-82.
15. Berner B, Akca D, Jung T, Muller GA, Reuss-Borst MA. Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. J Rheumatol 2000; 27: 1128-35.
16. Saunders S, Jalkanen M, O'Farrell S, Bernfield M. Molecular cloning of syndecan, an integral membrane proteoglycan. J Cell Biol 1989; 108: 1547-56.
17. Day R, Ilyas M, Daszak P, Talbot I, Forbes A. Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy. Dig Dis Sci 1999; 44: 2508-15.
18. Fernig DG, Gallagher JT. Fibroblast growth factors and their receptors: an information network controlling tissue growth, morphogenesis and repair. Prog Growth Factor Res 1994; 5: 353-77.
19. Day R, Forbes A. Heparin, cell adhesion and pathogenesis of inflammatory bowel disease. Lancet 1999; 354: 62-4.
20. Beck PL, Podolsky DK. Growth factors in inflammatory bowel disease. Inflamm Bowel Dis 1999; 5: 44-60.
21. Lawrance IC, Maxwell L. Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease. Inflamm Bowel Dis 2001; 7: 226-36.
22. Ierardi E, Giorgio F, Piscitelli D et al. Altered molecular pattern of mucosal healing in Crohn's disease fibrotic stenosis. World J Gastrointest Pathophysiol 2013; 15: 53-8.
23. Tursi A, Elisei W, Brandimarte G et al. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumor necrosis factor-alpha in diverticular disease of the colon: a case-control study. Neurogastroenterol Motil 2012; 24: 836-e396.
24. Hansen O, Graupe F, Stock W. Prognostic factors in perforating diverticulitis of the large intestine. Chirurg 1998; 69: 443-9.
25. Ierardi E, Giorgio F, Rosania R et al. Mucosal assessment of tumor necrosis factor alpha levels on paraffined samples: a comparison between immunohistochemistry and real time polymerase chain reaction. Scand J Gastroenterol 2010; 45: 1007-8.
26. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000; 25: 169-93.
27. Tursi A, Brandimarte G, Elisei W et al. Assessment and grading of mucosal inflammation in colonic diverticular disease. J Clin Gastroenterol 2008; 42: 699-703.
28. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1756-67.
29. Tursi A. Segmental colitis associated with diverticulosis: complication of diverticular disease or autonomous entity? Dig Dis Sci 2011; 56: 27-34.
30. Tursi A, Elisei W, Brandimarte G et al. Mucosal tumour necrosis factor α in diverticular disease of the colon is overexpressed with disease severity. Colorectal Dis 2012; 14: e258-63.
31. Humes DJ, Simpson J, Smith J et al. Visceral hypersensitivity in symptomatic diverticular disease and the role of neuropeptides and low grade inflammation. Neurogastroenterol Moti 2012; 24: 318-e163.
32. Meijer MJ, Mieremet-Ooms MA, van der Zon AM et al. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis 2007; 39: 733-9.
33. Principi M, Day R, Marangi S et al. Differential immunohistochemical expression of syndecan-1 and tumor necrosis factor alpha in colonic mucosa of patients with Crohn's disease. Immunopharmacol Immunotoxicol 2006; 28: 185-95.
34. Humes DJ, West J. Role of acute diverticulitis in the development of complicated colonic diverticular disease and 1-year mortality after diagnosis in the UK: population-based cohort study. Gut 2012; 61: 95-100.